Xencor In Licensing Agreement

Monrovia-based Xencor, which develops proteins and antibodies, announced Tuesday that it is in a licensing and commercialization agreement with Boehringer Ingelheim. The two will apply Xencor's technology platform to Boehringer Ingelheim's antibody drug candidates. The deal includes an upfront payment, license fees, milestone, and royalty payments. Specific financials were not disclosed.